A Phase 1b/2 Study of MEDI4736 in Combination With tremelimumab, MEDI4736 Monotherapy, and tremelimumab Monotherapy in Subjects With Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 1
Completed
- Conditions
- Gastric or Gastroesophageal Junction Adenocarcinoma
- Registration Number
- JPRN-jRCT2080223020
- Lead Sponsor
- AstraZeneca
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
1. Male and female subjects
2. 18 years and older
3. Histological or cytological confirmation of metastatic or recurrent gastric or gastroesophageal junction adenocarcinoma
4. Subjects must have received and have progressed, or are refractory to standard regimens
5. Subjects must have at least one lesion amenable to biospy
Exclusion Criteria
1. Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment
2. Previous immunotherapy
3. Concurrent or prior use of immunosuppressive medication with 14 days
4. Active or prior documented autoimmune or inflammatory disease within 3 years with some exceptions
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method safety<br>-
- Secondary Outcome Measures
Name Time Method safety<br>efficacy<br>-